中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

不可忽视的重症肝病——缺血性肝炎

祝凯 许红梅

引用本文:
Citation:

不可忽视的重症肝病——缺血性肝炎

DOI: 10.3969/j.issn.1001-5256.2022.010.042
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:祝凯负责拟定写作思路,整理文献,撰写并修改论文;许红梅负责指导撰写、修改论文并审查稿件。
详细信息
    通信作者:

    许红梅,xuhongm0095@sina.com

Ischemic hepatitis: A severe liver disease that cannot be neglected

More Information
  • 摘要: 缺血性肝炎在ICU临床日益多见,预后往往较差。其发病机制复杂,临床表现缺乏特异性,辅助检查方法有限,诊断标准及治疗方法尚未统一。早期识别和治疗对缺血性肝炎尤为重要。本文总结了缺血性肝炎的流行病学、发病机制、临床表现、辅助检查、诊断、治疗及相关研究进展,以期提高临床医师对该病的认识,促进对该病的及时诊断和治疗。

     

  • [1] BIRGENS HS, HENRIKSEN J, MATZEN P, et al. The shock liver. Clinical and biochemical findings in patients with centrilobular liver necrosis following cardiogenic shock[J]. Acta Med Scand, 1978, 204(5): 417-421.
    [2] BYNUM TE, BOITNOTT JK, MADDREY WC. Ischemic hepatitis[J]. Dig Dis Sci, 1979, 24(2): 129-135. DOI: 10.1007/BF01324740.
    [3] GARLAND JS, WERLIN SL, RICE TB. Ischemic hepatitis in children: diagnosis and clinical course[J]. Crit Care Med, 1988, 16(12): 1209-1212. DOI: 10.1097/00003246-198812000-00006.
    [4] LIGHTSEY JM, ROCKEY DC. Current concepts in ischemic hepatitis[J]. Curr Opin Gastroenterol, 2017, 33(3): 158-163. DOI: 10.1097/MOG.0000000000000355.
    [5] BREU AC, PATWARDHAN VR, NAYOR J, et al. A multicenter study into causes of severe acute liver injury[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1201-1203. DOI: 10.1016/j.cgh.2018.08.016.
    [6] JONSDOTTIR S, ARNARDOTTIR MB, ANDRESSON JA, et al. Prevalence, clinical characteristics and outcomes of hypoxic hepatitis in critically ill patients[J]. Scand J Gastroenterol, 2022, 57(3): 311-318. DOI: 10.1080/00365521.2021.2005136.
    [7] TAPPER EB, SENGUPTA N, BONDER A. The incidence and outcomes of ischemic hepatitis: A systematic review with Meta-analysis[J]. Am J Med, 2015, 128(12): 1314-1321. DOI: 10.1016/j.amjmed.2015.07.033.
    [8] JUNG C, FUERNAU G, EITEL I, et al. Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock[J]. Clin Res Cardiol, 2017, 106(5): 341-349. DOI: 10.1007/s00392-016-1060-3.
    [9] van den BROECKE A, van COILE L, DECRUYENAERE A, et al. Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis[J]. Ann Intensive Care, 2018, 8(1): 15. DOI: 10.1186/s13613-018-0356-z.
    [10] LEE YI, KANG MG, KO RE, et al. The impact of hypoxic hepatitis on clinical outcomes after extracorporeal cardiopulmonary resuscitation[J]. J Clin Med, 2020, 9(9): 2994. DOI: 10.3390/jcm9092994.
    [11] CHOI SH, JANG HJ, SUH YJ, et al. Clinical implication of hypoxic liver injury for predicting hypoxic hepatitis and in-hospital mortality in ST elevation myocardial infarction patients[J]. Yonsei Med J, 2021, 62(10): 877-884. DOI: 10.3349/ymj.2021.62.10.877.
    [12] YAO JX, LYU L, LONG C, et al. Prevalence, risk factors, and prognosis of ischemic hepatitis during venous-arterial extracorporeal membrane oxygenation[J]. Int J Anesthesiol Resuscitation, 2017, 38(11): 987-992. DOI: org/ 10.1016/j.transproceed.2020.10.031.

    姚婧鑫, 吕琳, 龙村, 等. 体外膜氧合治疗期间缺血性肝炎发病率、危险因素及预后[J]. 国际麻醉学与复苏杂志, 2017, 38(11): 987-992. DOI: org/ 10.1016/j.transproceed.2020.10.031.
    [13] HUANG H, LI H, CHEN S, et al. Prevalence and characteristics of hypoxic hepatitis in COVID-19 patients in the intensive care unit: A first retrospective study[J]. Front Med (Lausanne), 2020, 7: 607206. DOI: 10.3389/fmed.2020.607206.
    [14] CAI HB, HUANG BX, ZHU ZS, et al. Analysis of clinical characteristics of hypoxic hepatitis in children[J]. Chin J Peds, 2016, 54(3): 201-204. DOI: 10.3760/cma.j.issn.0578-1310.2016.03.009.

    蔡华波, 黄宝兴, 朱忠生, 等. 儿童缺氧性肝炎临床特点分析[J]. 中华儿科杂志, 2016, 54(3): 201-204. DOI: 10.3760/cma.j.issn.0578-1310.2016.03.009.
    [15] PANWAR V, RANAWEERA P. Ischemic hepatitis secondary to hepatic artery steal in a patient with celiac artery stenosis and severe postural hypotension[J]. Catheter Cardiovasc Interv, 2011, 78(5): 799-801. DOI: 10.1002/ccd.22994.
    [16] HORVATITS T, DROLZ A, TRAUNER M, et al. Liver injury and failure in critical illness[J]. Hepatology, 2019, 70(6): 2204-2215. DOI: 10.1002/hep.30824.
    [17] WASEEM N, CHEN PH. Hypoxic hepatitis: A review and clinical update[J]. J Clin Transl Hepatol, 2016, 4(3): 263-268. DOI: 10.14218/JCTH.2016.00022.
    [18] LI DZ, YOU SL, LYU S, et al. Diagnosis and treatment of special subacute liver failure: A case report[J]. Chin Hepatol, 2021, 26(7): 819-821. DOI: 10.14000/j.cnki.issn.1008-1704.2021.07.030.

    李东泽, 游绍莉, 吕飒, 等. 1例特殊亚急性肝功能衰竭患者的诊治[J]. 肝脏, 2021, 26(7): 819-821. DOI: 10.14000/j.cnki.issn.1008-1704.2021.07.030.
    [19] KHAN H, PHILLIPOSE J, AHMED M, et al. Athlete's hepatitis in a young healthy marathon runner[J]. Case Rep Gastroenterol, 2018, 12(1): 176-181. DOI: 10.1159/000488446.
    [20] CIOBANU AO, GHERASIM L. Ischemic hepatitis-intercorrelated pathology[J]. Maedica (Bucur), 2018, 13(1): 5-11. DOI: 10.26574/maedica.2018.13.1.5
    [21] HENRION J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis[J]. Acta Gastroenterol Belg, 2000, 63(4): 336-347.
    [22] MARUYAMA H, SHⅡNA S. Antioxidant therapy on ischemic hepatitis: here we are and where do we go?[J]. Hepatol Int, 2020, 14(4): 456-459. DOI: 10.1007/s12072-020-10044-y.
    [23] XU D, TIAN Y, XIA Q, et al. The cGAS-STING pathway: Novel perspectives in liver diseases[J]. Front Immunol, 2021, 12: 682736. DOI: 10.3389/fimmu.2021.682736.
    [24] RABIE MA, ZAKI HF, SAYED HM. Telluric acid ameliorates hepatic ischemia reperfusion-induced injury in rats: Involvement of TLR4, Nrf2, and PI3K/Akt signaling pathways[J]. Biochem Pharmacol, 2019, 168: 404-411. DOI: 10.1016/j.bcp.2019.08.001.
    [25] BUTLER DC, LEWIN DN, BATALIS NI. Differential diagnosis of hepatic necrosis encountered at autopsy[J]. Acad Forensic Pathol, 2018, 8(2): 256-295. DOI: 10.1177/1925362118782056.
    [26] RAURICH JM, LLOMPART-POU JA, FERRERUELA M, et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality[J]. J Anesth, 2011, 25(1): 50-56. DOI: 10.1007/s00540-010-1058-3.
    [27] TAYLOR RM, TUJIOS S, JINJUVADIA K, et al. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis[J]. Dig Dis Sci, 2012, 57(3): 777-785. DOI: 10.1007/s10620-011-1918-1.
    [28] ABOELSOUD MM, JAVAID AI, AL-QADI MO, et al. Hypoxic hepatitis-its biochemical profile, causes and risk factors of mortality in critically-ill patients: A cohort study of 565 patients[J]. J Crit Care, 2017, 41: 9-15. DOI: 10.1016/j.jcrc.2017.04.040.
    [29] JÄGER B, DROLZ A, MICHL B, et al. Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis[J]. Hepatology, 2012, 56(6): 2297-2304. DOI: 10.1002/hep.25896.
    [30] PRIMA V, CAO M, SVETLOV SI. ASS and SULT2A1 are novel and sensitive biomarkers of acute hepatic injury-A comparative study in animal models[J]. J Liver, 2013, 2(1): 1000115. DOI: 10.4172/2167-0889.1000115.
    [31] HORVATITS T, KNEIDINGER N, DROLZ A, et al. Prognostic impact of ICG-PDR in patients with hypoxic hepatitis[J]. Ann Intensive Care, 2015, 5(1): 47. DOI: 10.1186/s13613-015-0092-6.
    [32] GHOSH A, ONSAGER C, MASON A, et al. The role of oxygen intake and liver enzyme on the dynamics of damaged hepatocytes: Implications to ischaemic liver injury via a mathematical model[J]. PLoS One, 2021, 16(4): e0230833. DOI: 10.1371/journal.pone.0230833.
    [33] GIANNINI EG, TESTA R, SAVARINO V. Liver enzyme alteration: a guide for clinicians[J]. CMAJ, 2005, 172(3): 367-379. DOI: 10.1503/cmaj.1040752.
    [34] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [35] LIU M, TAN W, YUAN W, et al. Development and validation of a diagnostic model to predict the risk of ischemic liver injury after Stanford A aortic dissection surgery[J]. Front Cardiovasc Med, 2021, 8: 701537. DOI: 10.3389/fcvm.2021.701537.
    [36] MAIWALL R, KUMAR A, BHADORIA AS, et al. Utility of N-acetylcysteine in ischemic hepatitis in cirrhotics with acute variceal bleed: a randomized controlled trial[J]. Hepatol Int, 2020, 14(4): 577-586. DOI: 10.1007/s12072-020-10013-5.
    [37] WANG G, LI JY, WENG YQ, et al. Protective effect of ulinastatin combined with dexmedetomidine on lung injury after cold ischemia-reperfusion in rats[J]. Eur Rev Med Pharmacol Sci, 2018, 22(17): 5712-5718. DOI: 10.26355/eurrev_201809_15839.
    [38] CHEN BH, LI WM. Effect of ulinastatin combined with ischemic preconditioning on hepatic ischemia-reperfusion injury in rats[J]. J Clin Hepatol, 2018, 34(2): 368-372. DOI: 10.3969/j.issn.1001-5256.2018.02.030.

    陈宝鹤, 李文美. 乌司他丁联合缺血预处理对大鼠肝缺血再灌注损伤的影响[J]. 临床肝胆病杂志, 2018, 34(2): 368-372. DOI: 10.3969/j.issn.1001-5256.2018.02.030.
    [39] ZHOU L, YANG X, SHU S, et al. Sufentanil protects the liver from ischemia/reperfusion-induced inflammation and apoptosis by inhibiting ATF4-induced TP53BP2 expression[J]. Inflammation, 2021, 44(3): 1160-1174. DOI: 10.1007/s10753-020-01410-x.
    [40] DENG J, FENG J, LIU T, et al. Beraprost sodium preconditioning prevents inflammation, apoptosis, and autophagy during hepatic ischemia-reperfusion injury in mice via the P38 and JNK pathways[J]. Drug Des Devel Ther, 2018, 12: 4067-4082. DOI: 10.2147/DDDT.S182292.
    [41] QIANG GH, WANG ZX, JI AL, et al. Sphingosine kinase 1 knockout alleviates hepatic ischemia/reperfusion injury by attenuating inflammation and oxidative stress in mice[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(3): 255-265. DOI: 10.1016/j.hbpd.2019.04.001.
    [42] ZHU P, DUAN L, CHEN J, et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice[J]. Hum Gene Ther, 2011, 22(7): 853-864. DOI: 10.1089/hum.2010.145.
    [43] HARRELL CR, FELLABAUM C, JOVICIC N, et al. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome[J]. Cells, 2019, 8(5): 467. DOI: 10.3390/cells8050467.
    [44] LOU G, CHEN Z, ZHENG M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases[J]. Exp Mol Med, 2017, 49(6): e346. DOI: 10.1038/emm.2017.63.
    [45] CHAO TY, HSIEH CC, KUO YH, et al. Bracteanolide A abrogates oxidative stress-induced cellular damage and protects against hepatic ischemia and reperfusion injury in rats[J]. Food Sci Nutr, 2021, 9(9): 4758-4769. DOI: 10.1002/fsn3.2374.
    [46] LI J, GUO C, WU J. Fucoidan: Biological activity in liver diseases[J]. Am J Chin Med, 2020, 48(7): 1617-1632. DOI: 10.1142/S0192415X20500809.
    [47] LI J, ZHANG Q, LI S, et al. The natural product fucoidan ameliorates hepatic ischemia-reperfusion injury in mice[J]. Biomed Pharmacother, 2017, 94: 687-696. DOI: 10.1016/j.biopha.2017.07.109.
    [48] FAN X, LIN L, CUI B, et al. Therapeutic potential of genipin in various acute liver injury, fulminant hepatitis, NAFLD and other non-cancer liver diseases: More friend than foe[J]. Pharmacol Res, 2020, 159: 104945. DOI: 10.1016/j.phrs.2020.104945.
    [49] SHIN JK, LEE SM. Genipin protects the liver from ischemia/reperfusion injury by modulating mitochondrial quality control[J]. Toxicol Appl Pharmacol, 2017, 328: 25-33. DOI: 10.1016/j.taap.2017.05.002.
    [50] ZHOU YB, HUA J, QI LL, et al. Protective effect of curcumin pre-treatment on liver of acute ischemia-reperfusion model rats[J]. J Jilin Univ(Med Edit), 2020, 46(2): 297-301, 433. DOI: 10.13481/j.1671-587x.20200215.

    周亚宾, 华进, 戚伶俐, 等. 姜黄素预处理对急性缺血再灌注模型大鼠肝脏的保护作用[J]. 吉林大学学报(医学版), 2020, 46(2): 297-301, 433. DOI: 10.13481/j.1671-587x.20200215.
    [51] MI K, HUANG R. Protective effect of urolithin A pretreatment in a rat model of hepatic ischemia-reperfusion injury[J]. J Clin Hepatol, 2020, 36(8): 1783-1787. DOI: 10.3969/j.issn.1001-5256.2020.08.021.

    米凯, 黄锐. 尿石素A预处理对肝缺血再灌注损伤大鼠模型的保护作用[J]. 临床肝胆病杂志, 2020, 36(8): 1783-1787. DOI: 10.3969/j.issn.1001-5256.2020.08.021.
  • 加载中
计量
  • 文章访问数:  899
  • HTML全文浏览量:  76
  • PDF下载量:  81
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-03-12
  • 录用日期:  2022-04-15
  • 出版日期:  2022-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回